The biotechnology company Accure Therapeutics, focused on developing innovative treatments for central nervous system disorders, has announced it has received €1.48 million in grants awarded by The Michael J. Fox Foundation (MJFF) and the Luxembourg National Research Fund (FNR). The funding will support the advancement of its drug candidate ACT-02. Headquartered at the Barcelona Science Park, the company expects to reach the clinical stage by the end of 2026.
The funding will drive two preclinical development programs for its groundbreaking drug, ACT-02—an innovative compound with potential disease-modifying properties. ACT-02 functions as an inhibitor of prolyl endopeptidase, a promising therapeutic target that has remained largely unexplored to date. The program is currently in an advanced preclinical stage, supported by positive efficacy results in vivo models of Parkinson’s disease, as well as favorable safety and toxicology data generated under GLP (Good Laboratory Practice) standards.
Accure Therapeutics has received a €1 million grant from The Michael J. Fox Foundation, which will be used to complete the preclinical activities required to finalize the Investigational New Drug (IND) studies, with the aim of submitting a request for entry into the Phase I clinical trial in 2026. This project is being carried out in collaboration with the Institute of Pharmacology, Toxicology, and Pharmacy at the Stiftung Tierärztliche Hochschule Hannover.
Meanwhile, the FNR BRIDGES program, managed by the Luxembourg National Research Fund (FNR), has provided €480,000 in funding to support the evaluation of ACT-02’s efficacy in highly translational Parkinson’s disease models using patient-derived induced pluripotent stem cells (iPSCs). The goal is to enhance patient selection and stratification for future precision medicine strategies.
“We are grateful to The Michael J. Fox Foundation and the Luxembourg National Research Fund for their financial support of our asset ACT-02 as a potential therapy for people with Parkinson’s disease. These two grants represent significant steps forward for us and our academic partners in developing our first-in-class drug candidate, ACT-02, for Parkinson’s disease,” says Laurent Nguyen, co-founder and CEO of Accure Therapeutics. “Following in the footsteps of ACT-01, our first neuroprotective program that recently achieved positive results in the Phase II clinical trial in neuro-ophthalmology, our goal with ACT-02 is to develop a game-changing drug,” Nguyen adds.
Image: From left to right, Laurent Nguyen, CEO; Pablo Villoslada, CSO; Rossella Medori, CMO and Paul Bikard, CFO. Image / Accure Therapeutics
La mejor actitud que podemos adoptar es la de trat...
The research team observed changes in head circumf...
AtCDF3 gene induced greater production of sugars a...
En nuestro post hablamos sobre este interesante tipo de célula del...
Many repetitive regions of the genome have been considered “junk DNA...
